Literature DB >> 19326705

Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic.

K Krishnamoorthy1, K T Harichandrakumar, A Krishna Kumari, L K Das.   

Abstract

BACKGROUND &
OBJECTIVES: During 2006, chikungunya emerged as a major ever known epidemic in India. Disability adjusted life years (DALY) is an appropriate summary measure of population health to express epidemiological burden of diseases. We estimated the burden due to suspected chikungunya using DALYs for the first time and compared between the states and also with the burden due to other vector-borne diseases in India. The economic burden was also assessed in terms of productivity loss.
METHODS: Data on the reported cases of fever/suspected cases of chikungunya from different states during 2006 in India were used. Years lived with disability (YLD) were calculated for non-fatal cases to estimate DALY. Since the disability weight for chikungunya is not available, the weights available for rheumatic arthritis, comparable to the disease outcome of chikungunya were used for the estimation. The burden was estimated for both acute and chronic cases. It is considered that about 11.5% of cases were reported to have extended morbidity with persisting arthralgia. For acute disease, the average duration of illness was considered to be nine days and for chronic cases it was six months on an average. The productivity loss due to income foregone by the working class was calculated using minimum official wage.
RESULTS: National burden of chikungunya was estimated to be 25,588 DALYs lost during 2006 epidemic, with an overall burden of 45.26 DALYs per million. It varied from 0.01 to 265.62 per million in different states. Karnataka alone contributed as high as 55% of the national burden. Persistent arthralgia was found to impose heavy burden, accounting for 69% of the total DALYs. The productivity loss in terms of income foregone was estimated to be a minimum of Rs. 391 million. INTERPRETATION &
CONCLUSION: The chikungunya epidemic in the year 2006 imposed heavy epidemiological burden and productivity loss to the community. The burden of chikungunya in terms of DALY was estimated for the first time. In view of re-emergence and spread of this infection in recent times it is warranted for derivation of disability weight for different health states of chikungunya to facilitate realistic estimates of DALYs. Quality epidemiological data from surveillance system to monitor vector-borne and zoonotic diseases would pave way for more realistic estimates of burden. The productivity loss in-terms of income foregone could be minimal as the estimation was made by using the minimum wage fixed by the government although the actual loss is expected to be higher.

Entities:  

Mesh:

Year:  2009        PMID: 19326705

Source DB:  PubMed          Journal:  J Vector Borne Dis        ISSN: 0972-9062            Impact factor:   1.688


  56 in total

Review 1.  Chikungunya virus: evolution and genetic determinants of emergence.

Authors:  Konstantin A Tsetsarkin; Rubing Chen; Michael B Sherman; Scott C Weaver
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

Review 2.  Expanding Integrated Vector Management to promote healthy environments.

Authors:  Karina M Lizzi; Whitney A Qualls; Scott C Brown; John C Beier
Journal:  Trends Parasitol       Date:  2014-07-12

3.  Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

Authors:  Chad J Roy; A Paige Adams; Eryu Wang; Kenneth Plante; Rodion Gorchakov; Robert L Seymour; Heather Vinet-Oliphant; Scott C Weaver
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

4.  Occurrence of Chronic Stage Chikungunya in the General Population of Martinique during the First 2014 Epidemic: A Prospective Epidemiological Study.

Authors:  Brieg Couzigou; Anne Criquet-Hayot; Emilie Javelle; Sandrine Tignac; Edith Mota; François Rigaud; Alizé Alain; Odile Troisgros; Sandrine Pierre-Francois; Sylvie Abel; Rishika Banydeen; André Cabié
Journal:  Am J Trop Med Hyg       Date:  2018-05-24       Impact factor: 2.345

5.  Intracellular ROS generated in chikungunya patients with persisting polyarthralgia can be reduced by Tinospora cordifolia leaf extract.

Authors:  Nilotpal Banerjee; Bibhuti Saha; Sumi Mukhopadhyay
Journal:  Virusdisease       Date:  2018-06-09

6.  Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication.

Authors:  André C Ferreira; Patrícia A Reis; Caroline S de Freitas; Carolina Q Sacramento; Lucas Villas Bôas Hoelz; Mônica M Bastos; Mayara Mattos; Natasha Rocha; Isaclaudia Gomes de Azevedo Quintanilha; Carolina da Silva Gouveia Pedrosa; Leticia Rocha Quintino Souza; Erick Correia Loiola; Pablo Trindade; Yasmine Rangel Vieira; Giselle Barbosa-Lima; Hugo C de Castro Faria Neto; Nubia Boechat; Stevens K Rehen; Karin Brüning; Fernando A Bozza; Patrícia T Bozza; Thiago Moreno L Souza
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

7.  Complete genome sequence of a chikungunya virus isolated in Guangdong, China.

Authors:  Xiao-Feng Li; Tao Jiang; Yong-Qiang Deng; Hui Zhao; Xue-Dong Yu; Qing Ye; Hong-Jiang Wang; Shun-Ya Zhu; Fu-Chun Zhang; E-De Qin; Cheng-Feng Qin
Journal:  J Virol       Date:  2012-08       Impact factor: 5.103

8.  Epidemiology, clinical manifestations, and diagnosis of Chikungunya fever: lessons learned from the re-emerging epidemic.

Authors:  Alladi Mohan; D H N Kiran; I Chiranjeevi Manohar; D Prabath Kumar
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

9.  HLA class II allele polymorphism in an outbreak of chikungunya fever in Middle Andaman, India.

Authors:  Itta Krishna Chaaithanya; Nagarajan Muruganandam; Maile Anwesh; Reesu Rajesh; Sruti R Ghosal; Chinnaiah Kartick; Kadiyala Nageswara Prasad; Karuppiah Muthumani; Paluru Vijayachari
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

Review 10.  Chikungunya virus and prospects for a vaccine.

Authors:  Scott C Weaver; Jorge E Osorio; Jill A Livengood; Rubing Chen; Dan T Stinchcomb
Journal:  Expert Rev Vaccines       Date:  2012-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.